Inventor · disambiguated record
Ian Holmes
Also filed as: HOLMES IAN · HOLMES IAN PETER
19 granted patents·16 pending applications·43 citations·filing 2004–2024
92Inventor score
Files withAZURA OPHTHALMICS LTD10GLAXO GROUP LTD6AUSPHERIX LTD4CANCER THERAPEUTICS CRC PTY LTD4HOLMES IAN PETER4
Top patents by PatentIndex Score
35 records- 0194US10875845B2Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2020·Granted Dec 29, 2020·4 cites·20 claims
- 0289US12017979B2MoleculesEna Respiratory Pty Ltd·Filed 2023·Granted Jun 25, 2024·2 cites·4 claims
- 0386US11459351B1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2021·Granted Oct 4, 2022·1 cites·16 claims
- 0484US11634411B2Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2020·Granted Apr 25, 2023·1 cites·1 claims
- 0584US9856252B22-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferaseCANCER THERAPEUTICS CRC PTY LTD·Filed 2014·Granted Jan 2, 2018·8 cites·16 claims
- 0678US2025042931A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2024·Application pending·0 cites
- 0776US12195557B2Optimised compoundsAxelia Oncology Pty Ltd·Filed 2018·Granted Jan 14, 2025·1 cites·5 claims
- 0875US9174946B2Selective FAK inhibitorsHOLMES IAN PETER·Filed 2012·Granted Nov 3, 2015·5 cites·3 claims
- 0974US2023357207A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2023·Application pending·0 cites
- 1073US2025066416A1Optimised compoundsAxelia Oncology Pty Ltd·Filed 2024·Application pending·0 cites
- 1172US7250439B2Matrix metalloproteinase inhibitorsGLAXO GROUP LTD·Filed 2004·Granted Jul 31, 2007·6 cites·3 claims
- 1272US2023348517A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2023·Application pending·0 cites
- 1371US7601729B2Matrix metalloproteinase inhibitorsGLAXO GROUP LTD·Filed 2004·Granted Oct 13, 2009·5 cites·15 claims
- 1471US2022332749A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2022·Application pending·0 cites
- 1570US7375248B2Inhibitors of matrix metalloproteinaseGLAXO GROUP LTD·Filed 2004·Granted May 20, 2008·4 cites·4 claims
- 1669US11643429B2Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2021·Granted May 9, 2023·0 cites·20 claims
- 1769US9012461B2FAK inhibitorsHOLMES IAN PETER·Filed 2012·Granted Apr 21, 2015·1 cites·27 claims
- 1868US7476759B2Matrix metalloproteinase inhibitorsGLAXO GROUP LTD·Filed 2004·Granted Jan 13, 2009·4 cites·5 claims
- 1965US8343986B2Matrix metalloproteinase inhibitorsGLAXO GROUP LTD·Filed 2009·Granted Jan 1, 2013·0 cites·19 claims
- 2063US9120761B2Selective FAK inhibitorsHOLMES IAN PETER·Filed 2012·Granted Sep 1, 2015·1 cites·22 claims
- 2156US2008227858A1Inhibitors of matrix metalloproteinaseGLAXO GROUP LTD·Filed 2008·Application pending·0 cites
- 2256US2024158375A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2021·Application pending·0 cites
- 2355US8263602B2Matrix metalloproteinase inhibitorsGAINES SIMON·Filed 2008·Granted Sep 11, 2012·0 cites·8 claims
- 2455US2022388950A1Novel moleculesAxelia Oncology Pty Ltd·Filed 2020·Application pending·0 cites
- 2554US2023399317A1Compounds and methods for the treatment of ocular disordersAZURA OPHTHALMICS LTD·Filed 2021·Application pending·0 cites
- 2652US2013324532A1Fak inhibitorsHOLMES IAN PETER·Filed 2012·Application pending·0 cites
- 2746US9266864B2VEGFR3 inhibitorsCANCER THERAPEUTICS CRC PTY LTD·Filed 2013·Granted Feb 23, 2016·0 cites·41 claims
- 2842US9238644B2VEGFR3 inhibitorsCANCER THERAPEUTICS CRC PTY LTD·Filed 2013·Granted Jan 19, 2016·0 cites·61 claims
- 2941US9421205B2FAK inhibitorsCANCER THERAPEUTICS CRC PTY LTD·Filed 2015·Granted Aug 23, 2016·0 cites·4 claims
- 3040US2014323346A1Binding agentGARVAN INST MED RES·Filed 2012·Application pending·0 cites
- 3137US2017226133A1Gold (I)-Phosphine Compounds as Anti-Bacterial AgentsAUSPHERIX LTD·Filed 2015·Application pending·0 cites
- 3237US2020147028A1Treatment of respiratory infection with a tlr2 agonistEna Therapeutics Pty Ltd·Filed 2018·Application pending·0 cites
- 3333US2018360856A1Anti-bacterial compoundsAUSPHERIX LTD·Filed 2016·Application pending·0 cites
- 3433US2018369258A1Anti-bacterial compounds based on amino-gold phosphine complexesAUSPHERIX LTD·Filed 2016·Application pending·0 cites
- 3531US2017204123A1Gold (I)-Phosphine Compounds as Anti-Bacterial AgentsAUSPHERIX LTD·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →